Local Recurrence of Breast Cancer in Patients with DCIS Depending of the Margin Assessment
(119)
E Colon, J Carlson - Karolinska University Hospital, Stockholm, Sweden
Pure Mucinous Carcinoma in Women 40 Years Old or Younger: Clinico-Pathological and Follow-Up Study
(270)
EA Slodkowska, AD Corben, J Catalano, E Brogi - Memorial Sloan Kettering Cancer Center, New York, NY
Neuroendocrine Carcinoma (NEC) of the Breast – Clinicopathological Study of 90 NEC Cases in Conjunction with 1505 Non-NEC Cases
(178)
T Kawasaki, K Mochizuki, T Kondo, H Yamauchi, S Inoue, M Inoue, N Oishi, T Yamane, T Nakazawa, D Niu, H Yagata, H Tsunoda, H Onishi, H Fujii, R Katoh - University of Yamanashi, Yamanashi, Japan; St. Luke´s International Hospital, Tokyo, Japan
Intracystic Papillary Carcinoma (IPC) of the Breast: A Clinicopathological Study of 125 Cases
(88)
I Alvarado-Cabrero, R Valencia-Cedillo, S Barroso-Bravo - Mexican Oncology Hospital, IMSS, Mexico, DF, Mexico
Can Tumor Cellularity Predict Outcomes in Primary Non- Treated Breast Carcinoma?
(243)
ES Reisenbichler, O Hameed - Brigham and Women´s Hospital, Boston, MA; Vanderbilt University, Nashville, TN
Dietary Stearate Is an Effective Complementary Agent to Paclitaxel in Reducing the Incidence and Tumor Burden of Breast Cancer Lung Metastasis
(163)
RW Hardy, G Rezonzew, X Zhao, R Desmond, GP Siegal - University of Alabama at Birmingham, Birmingham, AL
Invasive Lobular Carcinoma and Oncotype Dx®: Impact of Pathology and Recurrence Score on Treatment Plan
(255)
DS Ross, LC Galman, J Catalano, LK Tan - Memorial Sloan-Kettering Cancer Center, New York
Breast Pathology Second Review Identifies Clinically Significant Discrepancies in 10% of Cases
(179)
L Khazai, LP Middleton, N Goktepe, BT Liu, AA Sahin - MD Anderson Cancer Center, Houston, TX
Outcomes Study of Atypical Ductal Hyperplasia and Ductal Carcinoma In Situ Treated with Excision
(240)
J Qian, A Rizki, J Chong, J Richey, J Ticar, L Shan, M Idowu - Virginia Commonwealth University, Richmond, VA
Do Combined Histopathological Features of ER Positive Breast Carcinoma Correlate with OncotypeDx Recurrence Score?
(138)
S Ehdaivand, RA Simon, C Zhang, MR Quddus, JJ Ou, J Xiong, K Hansen, MM Lomme, W Shen, MM Steinhoff, WD Lawrence, CJ Sung - Brown University/Women & Infants Hospital, Providence, RI
Progesterone Receptor and Ki-67 Immunohistochemistry Predict Oncotype Dx® Recurrence Score in Lymph Node Negative and Positive Breast Cancers
(271)
LS Spruill, JR McEvoy - Medical University of South Carolina, Charleston, SC; Roper St. Francis Heathcare, Charleston, SC
Can GP88 Expression Serve as an Additional Surrogate Marker for Oncotype DX Recurrence Score?
(183)
M Koka, LB Goicochea, G Serrero, K Tkaczuk, B Yue, K Tuttle, OB Ioffe - University of Maryland School of Medicine, Baltimore, MD; University of Maryland Greenebaum Cancer Center, Baltimore, MD; A&G Pharmaceutical Inc., Columbia, MD
The University of Kentucky Model for Selecting Breast Cancer Patients for Oncotype DX Testing
(153)
S Frame, M Burge, N Miller, Y Brill, R Matnani, P McGrath, M-L Fjallskog, LM Samayoa - University of Kentucky, Lexington, KY; VAMC, Lexington, KY; Uppsala University, Uppsala, Sweden
Patterns of Oncotype DX Recurrence Scores – Analysis Based on Levels of ER & PR Expression and Proliferation Markers
(102)
M Burge, S Frame, P McGrath, E Romond, M-L Fjallskog, C Ahlin, M Cibull, Y Brill, LM Samayoa - University of Kentucky, Lexington, KY; Uppsala University, Uppsala, Sweden
button next to any title to add to Itinerary Planner...
Add
